BWXT Medical and NorthStar Medical Radioisotopes Sign Supply Agreement Supporting Actinium-225 Production
(OTTAWA, Ontario and Beloit, WI – July 22, 2024) – BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells […]
BWXT to Evaluate Locations for Building New Nuclear TRISO Fuel Production Facility to Support Advanced Reactor Deployment
BWXT and Wyoming Energy Authority Sign Cooperation Agreement to Examine Potential Construction Options in the State (LYNCHBURG, Va. – July 18, 2024) – BWX Technologies, Inc. (NYSE: BWXT) is evaluating locations for a potential new TRISO nuclear fuel production facility to support anticipated future demand for advanced reactor deployment. As part of this effort, BWXT’s […]
BWXT Supports Peterborough’s Dragon Boat Festival
Employees from BWXT’s Peterborough facility have participated in Peterborough’s Dragon Boat Festival since 2002. This year, the BWXT Xtreme Paddlers team raised over $5,500 for Peterborough Regional Health Centre to fund cancer treatment right here in the community. BWXT is a bronze sponsor of this important community event.
BWXT Awarded Phase Two of Microreactor Evaluation Contract for State of Wyoming
(LYNCHBURG, Va. – June 17, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced the award of the second phase of a contract with the Wyoming Energy Authority to assess the viability of deploying small-scale nuclear reactors in the state as a source of resilient and reliable energy to augment existing power generation resources. Under […]
BWXT-led Team Awarded $30 Billion Management and Operating Contract for National Nuclear Security Administration’s Pantex Plant
(LYNCHBURG, Va. – June 14, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract award from the U.S. Department of Energy, National Nuclear Security Administration (DOE/NNSA) for management and operations of the Pantex Plant. Following an initial term of five years, NNSA has the ability to award three additional five-year option periods. If […]
BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
(OTTAWA, Ontario – June 7, 2024) – BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope used in targeted alpha therapies (TATs) that combine the isotope with specific tumor-seeking targeting vectors […]
BWXT employees trained as Nuclear Ambassadors
BWX Technologies, Inc. (BWXT) has partnered with the American Nuclear Society to offer customized ANS Nuclear Ambassadors training to BWXT employees. The training kicked off in February with an initial two-hour virtual event that was presented to more than 60 BWXT employees, and it wrapped in April. BWXT is the first company to participate in ANS’s newly […]
2024 Spring Community Newsletters Available
The Spring 2024 Community Newsletters are now available here. Contact us at [email protected] if you want to join our email list to receive regular updates (including our newsletters) direct to your inbox.
2023 Annual Compliance Reports Available
Each year, BWXT Nuclear Energy Canada (BWXT NEC) submits comprehensive Annual Compliance Reports (ACR) to Canada’s nuclear regulator, the Canadian Nuclear Safety Commission (CNSC) for the Peterborough and Toronto operations. The purpose of these reports is to demonstrate that BWXT NEC has successfully met the requirements of the Nuclear Safety and Control Act and its […]
BWX Technologies Reports First Quarter 2024 Results
Lynchburg, VA – May 6, 2024 – BWX Technologies, Inc. (NYSE: BWXT) (“BWXT”, “we”, “us” or the “Company”) reported first quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. “We started 2024 with solid operating results in each of our business segments, both financially and strategically,” said Rex. D. Geveden, president and chief executive […]
